Looking forward to the ISPE Annual Meeting in Washington DC!
The DSRU team will be attending the 41st Annual Meeting of the International Society for Pharmacoepidemiology (ISPE) in Washington on 23rd-26th August.
We will present a snapshot of the wide variety of observational studies that we conduct, both at the DSRU and via a number of collaborations, in two presentations and 8 research posters.
Dr Sandeep Dhanda (Senior Drug Safety Research Physician) and Samantha Lane (Senior Epidemiologist) from the DSRU research team will present studies covering additional risk minimisation measures (aRMMs), signal detection, active surveillance of flu vaccine safety and European collaborative post-authorisation safety studies (PASS) on several Covid-19 vaccines. Sandeep Dhanda will present our evaluation of a signal of congenital abnormality following use of a fertility drug by means of a disproportionality analysis using global spontaneous reports from VigiBase database and a systematic literature review to contextualise the signal.
The DSRU is the UK’s leading unit for pharmacovigilance and pharmacoepidemiology and we offer a range of real-world observational studies including drug utilisation studies, CPRD studies, registries and a pharmacoepidemiology and real-world service for small and medium companies. As an active member of the VAC4EU consortium, the DSRU also conduct multi-database network studies across Europe.
The DSRU will also be presenting the new distance learning version of its popular MSc in Pharmacovigilance during the Academic Showcase at the conference’s Welcome Reception. The DSRU is a leading provider of training in pharmacovigilance and pharmacoepidemiology and is delighted to open registration for this distance learning course, to enable students from around the world to join our many successful graduates in obtaining an industry-recognised postgraduate qualification in pharmacovigilance. Find out more here: https://www.dsru.org/distance-learning/
If you are attending the ISPE conference, do come and say hello! Sandeep and Samantha can be found at the VAC4EU booth (#500) between sessions and would be delighted to discuss the DSRU’s capabilities and the research they’re presenting in Washington. To schedule a meeting with them email us on enquiries@ dsru.org.
Discover the breadth of DSRU research and expertise via our oral presentations and posters at ISPE Washington:
Sunday 24th August
Posters:
(A-235) Evaluation of Effectiveness of Additional Risk Minimisation Measures (aRMMs): perspectives from a UK non-interventional post authorisation safety study (PASS). S. Dhanda, M. Davies, J. Denyer, D. Roy.
(A337) Dependence of the Data Source on the Positive Predictive Value in the Retrospective Case Validation of Thrombosis and Thrombocytopenia Syndrome cases using Real-World Data. A. Yeomans, T. Aurelius, D. Roy, K. Morton, et al.
(A-339) 2024 interim results from the VAC4EU post-authorisation safety study (PASS) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) in Europe. Daniel Weibel, et al.
(A-332) Monitoring safety of Moderna COVID-19 vaccines in pregnancy: a multi-database study in Denmark, Norway, Spain and the United Kingdom. A regulator-mandated post-authorisation safety study in the VAC4EU network (EUPAS44450). V. Ehrenstein, et al.
Tuesday 26th August
Oral Presentations:
(5D-02) Assessing a Signal of Congenital Anomalies Following Dydrogesterone Exposure in Pregnancy: Results From a Disproportionality Analysis (DPA) and Systematic Review. A.Bobbins, T.Aurelius, A.Yeomans, S.Dhanda, D.Roy, M.Davies.
(5C-01) Monitoring the Safety of mRNA-1273 COVID-19 Vaccine (Elasomeran) in the General Population: Results of a Regulator-mandated Post-authorisation Safety Study in Denmark, Norway, Spain, and the United Kingdom (EUPAS44273). Signe Sørup, et al.
Posters:
(C-253) Active and Passive Safety Surveillance in Children Receiving Fluenz® Tetra Vaccination in England During Influenza Seasons - from 2014/2015 to 2022/2023. K. Morton, S. Dhanda, J. Denyer, D. Morris, T. Aurelius, D. Roy.
(SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study. Joan Forns, et al.
(SLC-054) Risk factors for myocarditis/pericarditis following mRNA-1273 vaccination: interim analysis of a VAC4EU case-cohort study. L. Zwiers et al.
(SLC-055) Clinical course and outcomes of myocarditis/pericarditis cases following mRNA-1273 vaccination compared to cases not following COVID-19 vaccination: interim analysis of a VAC4EU cohort study. L. Zwiers, et al.